United Therapeutics Corporation
NASDAQ:UTHRBiotechnology
-$18.01 today
- Market cap
- $24.59B
- Beta
- 0.57
- P/E (TTM)
- 18.0
- EPS (TTM)
- $29.60
Volume 0.42M
Average 0.52M
UTHR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
United Therapeutics CorporationNASDAQ: UTHR
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures grows, but more slowly than its trailing trend
Q2 FY2026 capital expenditures of $108M (cash outflow) rose 73.6% year over year, behind the +97.2% change in trailing-twelve-month capital expenditures. Sequentially, it rose 7.1% from the prior quarter. Over 3 fiscal years it compounded at +55.4% a year.
Context
- Capital expenditures amounted to 16.4% of revenue in FY2025, up 7.8 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +73.6% toward the trailing-twelve-month pace of +97.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (520.5M) USD
- Year-over-year change
- -111.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (520.5M) | -111.2% |
| FY2024 | 2024-12-31 | (246.5M) | -7.0% |
| FY2023 | 2023-12-31 | (230.4M) | -66.0% |
| FY2022 | 2022-12-31 | (138.8M) | -14.9% |
| FY2021 | 2021-12-31 | (120.8M) | — |
Capital Expenditures vs competitors
How UTHR compares with its peers on the latest reported figures
- UTHR's LTM Jun 2026 capital expenditures of $592.2M is the largest of the 5 companies compared; the peer median is $18.69M.
- Its year-over-year change of +97.2% is the 3rd highest of 4, against a peer median of +133.8%.
- Capital expenditures amounts to 18.8% of revenue for UTHR, versus a peer median of 4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $592.2M | +97.2% | +55.4% | 18.8% | |
| LTM Jun 2026 | $58.75M | +144.6% | +48.8% | 5.2% | |
| LTM Sep 2026 | $18.86M | -13.1% | +27.0% | 2.9% | |
| LTM Jun 2026 | $18.52M | +133.8% | +94.2% | 4.1% | |
| LTM Mar 2026 | $452.02K | — | -62.0% | — | |
| Peer median (excluding UTHR) | $18.69M | +133.8% | +37.9% | 4.1% | |
Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 475.8M | 727.3M | 984.8M | 1.2B | 1.33B |
| Depreciation & Amortization | 49.9M | 51.3M | 53.2M | 72.5M | 85.6M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 97.7M |
| Stock-Based Compensation | 138.5M | 106.8M | 39.1M | 144M | 147.7M |
| Change in Working Capital | (174.2M) | (141.2M) | (97.8M) | (60.2M) | (106.4M) |
| Accounts Receivables | (41.3M) | (21.7M) | (58.5M) | (400K) | (70.9M) |
| Inventory | (7.5M) | (13.4M) | (13.6M) | (46.9M) | (52.6M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 97.9M |
| Other Working Capital | (125.4M) | (106.1M) | (25.7M) | (12.9M) | (80.9M) |
| Other Non-Cash Items | 108.2M | 58.3M | (1.3M) | (24.3M) | 2M |
| Operating Cash Flow | 598.2M | 802.5M | 978M | 1.33B | 1.56B |
| Capital Expenditures | (120.8M) | (138.8M) | (230.4M) | (246.5M) | (520.5M) |
| Acquisitions (Net) | 0 | (1.5M) | (89.2M) | (30.5M) | 0 |
| Purchases of Investments | (1.9B) | (1.71B) | (2.51B) | (1.65B) | (3.46B) |
| Sales of Investments | 1.53B | 1.03B | 2.14B | 2.37B | 1.58B |
| Other Investing Activities | 0 | 3.5M | (23M) | (28.5M) | 1.85B |
| Investing Cash Flow | (486.9M) | (811.5M) | (719.6M) | 417.2M | (551.3M) |
| Debt Repayment | 0 | 0 | (100M) | (400M) | (300M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 183.1M |
| Common Stock Repurchased | (10.8M) | (11.4M) | (13.8M) | (1.01B) | (1B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 55.6M | 86.8M | 101.9M | 157.4M | (33.1M) |
| Financing Cash Flow | 44.8M | 75.4M | (11.9M) | (1.25B) | (1.15B) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 156.1M | 66.4M | 246.5M | 489.5M | (140.1M) |
| Free Cash Flow | 477.4M | 663.7M | 747.6M | 1.08B | 1.04B |
United Therapeutics Corporation
NASDAQ:UTHR
Intrinsic Alpha fair value
Locked
Current Price
$577.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.